---All---
  • ---All---
  • Accession
  • Catalog #

ACO2 Antibody (C-term)Purified Rabbit Polyclonal Antibody (Pab)

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AP7561b 0.1 mg 400 ul In Stock $ 255.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

ACO2 Antibody (C-term) - Product info

ApplicationIHC, WB
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionQ99798
ReactivityHuman
Concentration0.25 mg/ml
IsotypeRabbit Ig
Calculated MW85425 Da

ACO2 Antibody (C-term) - Additional info

Gene ID 50
Other Names
ACO2; Aconitate hydratase, mitochondrial; Citrate hydro-lyase
Target/Specificity
This ACO2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 633~662 amino acids from the C-terminal region of human ACO2.
Dilution
IHC~~1:10~50
WB~~1:50~100
Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
ACO2 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures.

ACO2 Antibody (C-term) - Protein Information

Name ACO2
Function
Catalyzes the isomerization of citrate to isocitrate via cis-aconitate (By similarity)
Cellular Location
Mitochondrion (By similarity).

ACO2 Antibody (C-term) - Related products

AP1936a: ACO2 Antibody (N-term)

AP1936c: ACO2 Antibody (Center)

AP7561b: ACO2 Antibody (C-term)

AP7561c: ACO2 Antibody (Center)

AP7561d: ACO2 Antibody (C-term)

RI10062: ACO2 predesign siRNA

BP1936a: ACO2 Antibody (N-term) Blocking Peptide

BP1936c: ACO2 Antibody (Center) Blocking Peptide

BP7561b: ACO2 Antibody (C-term) Blocking Peptide

BP7561c: ACO2 Antibody (Center) Blocking Peptide

BP7561d: ACO2 Antibody (C-term) Blocking Peptide

ACO2 Antibody (C-term) - Application data

  • Formalin-fixed and paraffin-embedded human breast carcinoma tissue reacted with ACO2 antibody (C-term) (Cat.#AP7651b), which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated.

  • Western blot analysis of ACO2 (arrow) using rabbit polyclonal ACO2 Antibody (C-term) (Cat.#AP7561b).293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the ACO2 gene (Lane 2) (Origene Technologies).

ACO2 Antibody (C-term) - Research Areas

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

ACO2 belongs to the aconitase/IPM isomerase family. It is an enzyme that catalyzes the interconversion of citrate to isocitrate via cis-aconitate in the second step of the TCA cycle. It was found to be one of the mitochondrial matrix proteins that are preferentially degraded by the serine protease 15(PRSS15), also known as Lon protease, after oxidative modification.

REFERENCES

Yu,Z.,Prostate 66 (10), 1061-1069 (2006) Tsui,K.H.,Asian J. Androl. 8 (3), 307-315 (2006) Ahmed,M.,J. Proteome Res. 4 (3), 931-940 (2005)